As pharma’s gene therapy pipeline matures, Catalent plans to invest more in the sector to meet high viral vector demand and advance growth. For the third quarter 2022, contract development manufacturing organization (CDMO) Catalent reported total revenues of $1.27 billion, an increase of 21% year-on-year. Catalent’s biologics segment came out as the top contributor to the CDMO’s financial performance, showcasing $698 million, representing net revenue growth of 30%over last year. Part of this success was due to “a notable increase”…

Pfizer says it is ceasing all future investment to build manufacturing capacity in Russia due to Vladimir Putin’s war against Ukraine. Putin’s universally criticized invasion of Ukraine has sent shockwaves across the world, with the pharma industry just one of many affected. Clinical trials have been disrupted, and the deepening conflict has driven concerns surrounding supply chains. Big Pharma has had a mixed response regarding its presence in the area, but several companies have announced they have scaled back activities…